HomeHealthUpgraded Chitra heart valve implanted in 40 patients in pilot project; results...

Upgraded Chitra heart valve implanted in 40 patients in pilot project; results promising

New Delhi, March 1 (IANS) The second-generation Chitra heart valve has been implanted in 40 patients in the last two years as part of the pilot clinical evaluation in order to tackle Rheumatic heart disease, the Centre said on Friday.

Rheumatic heart disease, which leads to the damage of heart valves needing prosthetic replacement, is a challenge in India, the Ministry of Science & Technology said.

In the 1980s, based on the estimate of the Indian Council for Medical Research (ICMR), six out of every 1,000 children had rheumatic fever and the young population at risk for valvular disease was estimated at 12 lakh.

The first Chitra Heart Valve was successfully implanted in a patient in 1990, and subsequent efforts to improve upon and scale up the product have led to the clinical use of close to 2,00,000 devices. Based on the feedback from the clinical trials of the earlier model, and post-market surveillance, few improvements were identified and implemented in the second-generation device.

Responding to India’s requirement for low-cost indigenous artificial heart valves, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), an autonomous institute of the Department of Science and Technology (DST), has developed the valve. After obtaining necessary regulatory approvals from the Central Drug Standards Control (CDSCO), the pilot clinical evaluation of the upgraded model TC2 was initiated in SCTIMST in the last two years and 40 valves were implanted in patients.

“The results are observed to be very promising and no specific complications were reported. Based on this positive outcome, a pivotal clinical trial has been planned and is expected to start by the end of 2024,” the department said.

The prototyping and preliminary proof of concept studies have been completed.

The institute has initiated the identification of a suitable industrial partner for taking this product to the clinic which is expected by 2026.

–IANS

shs/pgh

Disclaimer

The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.

Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

For any legal details or query please visit original source link given with news or click on Go to Source.

Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.

If you are not willing to accept this disclaimer then we recommend reading news post in its original language.

RELATED ARTICLES
- Advertisment -

Most Popular